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Abstract
The arenavirus family contains several important human pathogens including Lassa fever virus (LASV), lymphocytic choriomeningitis virus 
(LCMV) and the New World clade B viruses Junin (JUNV) and Machupo (MACV). Previously, a-dystroglycan (a-DG) was identified as a 
receptor recognized by LASV and certain strains of LCMV. However, other studies have suggested that ct-DG is probably not used by the clade B 
viruses, and the receptor(s) for these pathogens is currently unknown. Using pseudotyped retroviral vectors displaying arenavirus glycoproteins 
(GPs), we are able to explore the role played by the GP in viral entry in the absence of other viral proteins. By examining the ability of the vectors 
to transduce DG knockout murine embryonic stem (ES) cells, we have confirmed that LASV has an absolute requirement for a-DG in these cells. 
However, the LCMV GP can still direct substantial entry into murine ES cells in the absence of a-DG, even when the GP from the clone 13 
variant is used that has previously been reported to be highly dependent on a-DG for entry. We also found that neither LASV or LCMV 
pseudotyped vectors were able to transduce human or murine lymphocytes, presumably due to the glycosylation state of a-DG in these cells. In 
contrast, the JUNV and MACV GPs displayed broad tropism on human, murine and avian cell types, including lymphocytes, and showed no 
requirement for a-DG in murine ES cells. These findings highlight the importance of molecules other than a-DG for arenavirus entry. An alternate 
receptor is present on murine ES cells that can be used by LCMV but not by LASV, and which is not available on human or murine lymphocytes, 
while a distinct and widely expressed receptor(s) is used by the clade B viruses.
© 2006 Elsevier Inc. All rights reserved.
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Introduction
The arenaviruses are rodent-borne pathogens which include 
five members classified by the Centers for Disease Control and 
Prevention as Category A biological agents, capable of posing a 
significant threat if used for bioterrorism purposes. Two major 
subgroups are recognized on the basis of sequence comparisons, 
the Old World and New World viruses, with the New World 
viruses further divided into clades A, B and C (Fig. 1). The most 
common human infections are caused by the Old World viruses, 
lymphocytic choriomeningitis virus (LCMV) and Lassa fever 
virus (LASV). While LCMV infections are usually asymptom­
atic or mild, LASV infection is characterized by pulmonary 
edema, respiratory distress, shock and bleeding from mucosal 
surfaces. LASV infection rates are estimated at over 300,000 per 
year, mostly in Western Africa. Serious illnesses are also 
associated with certain New World clade B viruses, including 
Junin (JUNV) and Machupo (MACV) viruses, the causative 
agents of Argentine and Bolivian hemorrhagic fevers, respec­
tively. Since studies of the highly pathogenic arenaviruses are 
hampered by the need for biosafety level (BSL)-4 containment 
laboratories, most of the available information about this family 
has come from studies of LCMV.
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Fig. 1. The Arenaviridae. The family is divided into New World and Old World viruses, with the New World viruses further divided into three clades. The strains that 
are pathogenic for humans are indicated.
Arenaviruses are enveloped, bisegmented single-stranded 
RNA viruses. Their entry into cells is directed by a fusion 
glycoprotein (GP) located in the outer lipid envelope of the 
virus. This protein is initially synthesized as a precursor 
protein, GPC, which is cleaved into two non-covalently 
linked subunits, an integral membrane protein, GP2, and a 
peripheral membrane protein, GP1. The binding site for the 
cellular receptor is contained within GP1 (Parekh and 
Buchmeier, 1986), while GP2 anchors the complex in the 
viral and host cell membranes (Bums and Buchmeier, 1991) 
and contains structural features typical of class I viral fusion 
proteins (Gallaher et al., 2001). We and others have 
demonstrated that arenavirus GPs can be incorporated into 
retroviral and lentiviral vector particles, generating functional 
surrogates of the arenavirus entry process that can be worked 
with under standard BSL-2 laboratory conditions (Beyer et 
al., 2002; Christodoulopoulos and Cannon, 2001; Kunz et al., 
2003). The use of pseudotyped retroviral vectors also 
simplifies the analysis of arenavirus entry as it is possible 
to study the function of GP in the absence of other factors 
that may influence infection by native viruses.
A cellular receptor for LASV, certain strains of LCMV and 
the New World clade C arenaviruses Oliveros and Latino has 
been identified as a-dystroglycan (a-DG) (Cao et al., 1998; 
Kunz et al., 2005; Spiropoulou et al., 2002). This is a peripheral 
membrane protein, non-covalently associated with |’>-DG, and 
widely expressed in most cells, where it serves as an anchor 
between the submembranous cytoskeleton and the extracellular 
matrix (Durbccj et al., 1998). Recently, it has been shown that 
the specific post-translational glycosylation of a-DG is 
necessary both for its interaction with the extracellular matrix 
(Michele and Campbell, 2003 ) and for its function as a receptor 
for LCMV (fmperiali et al., 2005; Kunz et al., 2005) and LASV 
(Kunz et al., 2005).
It is also clear that a-DG is not the only receptor to be used 
by this family of viruses. Several isolates of LCMV have been 
shown capable of infecting murine ES cells knocked-out for a- 
DG, for example, variants WE2.2 and PBL364 gave wild-type 
infection rates on the knockout cells (Smelt et al., 2001; Kunz et 
al., 2004). Similarly, representative clade A (Parana) and clade 
B (Amapari) New World viruses have been shown to infect 
murine ES cells independently of a-DG (Spiropoulou et al., 
2002).
In this report, we used pseudotyped retroviral vectors to 
examine cell tropism and receptor usage by both Old World and 
New World viruses and in particular to further investigate the 
requirement for a-DG. Our data demonstrate that a-DG plays 
no role in the entry of the clade B viruses, JUNV and MACV, 
and provide additional evidence that alternate, non-a-DG 
receptor molecules can be used by LCMV.
Results
Generation of retroviral vectors pseudotyped with arenavirus 
GPs
In order to examine GP-receptor interactions during 
arenavirus entry, we generated a panel of retroviral vector 
particles pseudotyped with the GPs from different pathogenic 
arenaviruses. The use of pseudotyped vectors allows to examine 
the arenavirus entry process in isolation from the rest of the 
virus life cycle and to study BSL-4 pathogens under standard 
BSL-2 laboratory conditions. The panel we used included the 
Old World viruses LASV and LCMV and the New World clade 
B viruses JUNV and MACV, together with the non-pathogenic 
clade B virus Tacaribe (TACV) (Fig. 1). For LCMV, we used 
GPs from both the prototypical Arm53b strain and a mutated 
version of the protein with the substitution F260L at the C- 
terminus of GP1 (Arm-F260L). This mutation corresponds to the 
single change present in the GP of clone 13, an immunosup­
pressive variant of Arm53b (Salvato et al., 1991) that is reported 
to have greater dependency on a-DG for entry (Smelt et al., 
2001).
Pseudotyped retroviral vectors were generated as previously 
described (Christodoulopoulos and Cannon, 2001; Soneoka et 
al., 1995). The vectors expressed GFP reporter genes, allowing 
us to measure the efficiency of GP function by measuring 
transduction rates (titer) by FACS analysis of target cells 
incubated with the vector particles. All vector stocks were 
initially titered on human 293A cells, which are efficiently 
transduced by all of the different vectors used. The average 
titers obtained for unconcentrated vector stocks are shown in 
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Fig. 2. We consistently observed that the titers for the vectors 
pseudotyped with the Old World GPs were one order of 
magnitude higher than those obtained with the New World clade 
B GPs. In addition, in each experimental pair tested, the titer of 
the Arm-F26()L vectors was slightly higher than those obtained 
with the Arm53b vectors, although the difference was not 
statistically significant when averaged out over 5 data sets.
Incorporation of arenavirus GPs into retroviral vector 
particles
In order to examine whether the variation in titer on 293A 
cells between the different pseudotyped vectors arose because 
of differences in the efficiency of incorporation of GPs into 
vector particles, we performed Western blot analysis on purified 
vector particles. However, this analysis was complicated by the 
fact that we could not find a broadly cross-reacting antibody that 
recognized all of the arenavirus GPs used in this study. For 
example, monoclonal antibody WE-83.6, directed against the 
LCMV GP2 subunit, recognized only the LASV and LCMV 
GP2 proteins (data not shown), while the anti-LASV GP1 
monoclonal antibody L52-161-6 recognized only the LASV 
protein (Fig. 3A). In contrast, the anti-JUNV monoclonal 
antibody QD04 AF03 (Sanchez et al., 1989) recognized 
proteins from both JUNV and LCMV, although it did not 
cross-react with MACV, TACV or LASV proteins (Fig. 3B and 
data not shown).
The proteins recognized by antibody QD04 AF03 for both 
the JUNV and LCMV pseudotyped vectors were approximately 
65 kDa (JUNV only) and 33 kDa. The 65 kDa species is 
probably the uncleaved JUNV GPC precursor as this species 
was more prevalent in cell lysates than in viral particles (data 
not shown), but the identity of the 33 kDa protein was more 
difficult to ascertain. Previously, the LCMV GP1 subunit has 
been reported to run at 44 kDa and the GP2 subunit at 35 kDa 
(Bums and Buchmeier, 1991), suggesting that the antibody is 
recognizing GP2 subunits. However, QD04 AF03 has been 
reported to recognize the JUNV GP1 subunit (York et al., 2005 ), 
where the size of the JUNV GP1 and GP2 subunits was found to
Fig. 2. Titers of pseudotyped retroviral vectors on 293A cells. Titer was 
determined by FACS analysis of cells to determine GFP expression, 48 h after 
transduction, and the values shown are the mean ± SD for 3-6 independent 
experiments.
be approximately 33 and 35 kDa respectively. To determine 
whether antibody QD04 AF03 was detecting the GP1 or GP2 
subunits of JUNV and LCMV, we performed Western analysis 
using deglycosylated viral proteins and compared the sizes of 
the bands we saw to the predicted molecular weights for the 
JUNV and LCMV GP1 and GP2 subunits. This analysis 
revealed that the anti-JUNV antibody was probably recognizing 
the GP1 subunits of both viruses (Fig. 3B ). The finding that the 
LCMV GP1 subunit runs at approximately 33 kDa in our 
system instead of the previously reported 44 kDa was 
unexpected. Possible explanations for this discrepancy include 
the fact that previous studies have used native viruses rather 
than pseudotyped vectors, and the different cell types used may 
result in different glycosylation patterns that affect the size of 
the mature cleaved GP1 subunit.
Interestingly, we detected a significant amount of unpro­
cessed JUNV GPC in viral particles, which was not seen with 
the LCMV GP (Fig. 3B). This suggests that the lower titers 
obtained for the clade B vectors on 293A cells could result from 
less efficient processing of the GPC precursor, although it is 
also possible that this difference arises from the ability of the 
antibody to detect the JUNV but not the LCMV GPC precursor. 
Alternatively, the differences between the titers of the clade B 
and Old World pseudotypes could reflect the use of different 
cellular receptors on the 293A cell surface. We note that the 
one-log differences in titer that we observed between the clade 
B and Old World vectors on 293A cells did not hold up for 
every cell line we tested (see below).
As stated above, the LCMV Arm-F260L variant always gave 
slightly higher titers on 293A cells than the parental Arm53b 
vectors, although this was not statistically significant (Fig. 2). 
The presence of leucine or isoleucine at position 260 is typical 
of the immunosuppressive strains of LCMV that cause 
persistent infections in mice (Sevilla et al., 2000) and which 
exhibit altered pathogenicity and tissue tropism in vivo (Ahmed 
and Oldstone, 1988; Ahmed et al., 1984; Sevilla et al., 2000; 
Smelt et al., 2001). Arm53b and clone 13 have been reported to 
show large differences in their in vitro affinities for a-DG, with 
clone 13 binding a-DG with 100-1000 times greater affinity 
than Arm53b in virus overlay protein binding assays (VOPBAs) 
(Sevilla et al., 2000; Smelt et al., 2001). In addition, clone 13 is 
significantly more dependent on the presence of a-DG to infect 
mouse ES cells (Kunz et al., 2004; Smelt et al., 2001).
To investigate the basis for the increase in titer resulting from 
the F260L substitution, we examined whether the LCMV Arm- 
F260L GP was incorporated at higher efficiency into retroviral 
vector particles. However, Western blot analysis revealed that 
both the GP1 and GP2 subunits of Arm-F260L were incorpo­
rated into retroviral particles at significantly lower levels than 
the Arm53b protein. Furthermore, higher levels of Arm-F260L 
GP1 were observed in the lysates of transfected cells when 
compared to Arm53b, which is consistent with a reduction in 
the incorporation of Arm-F260L GP into retroviral particles. We 
also observed that the F260L mutant consistently suppressed the 
production of the retroviral vector particles, as measured by the 
amount of MLV CA protein in the supernatant (Fig. 3C). Taken 
together, these findings suggest that the single F260L change
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37 kDa
50 kDa
25 kD
75 kDa
Estimated MW (deglycosylated)
GP1 GP2 GPC
LCMV 23.6 26.4 50
JUNV 22 27 49
Ctrl, virions deglycosylated 
anti-JUNV GP1
virions, anti-LCMV GP2
Fig. 3. Incorporation of arenavirus GPs into retroviral vectors. (A) Western blots of pseudotyped retroviral vector particles, probed with anti-JUNV GP1 antiserum or 
anti-LASV GP1 monoclonal antibody. The vector particles were concentrated by ultracentrifugation through a sucrose cushion. The positions of the GPC and GP1 
subunits are indicated. (B) Western analysis of control and deglycosylated vector particles probed with the anti-JUNV GP1 antiserum. Comparison of the sizes of the 
deglycosylated proteins (GPC*  and GP1*)  indicates that the antibody recognizes the GP1 subunits. (C) Comparison of levels of Arm53b and Arm-F26oL GP in cell 
lysates and retroviral particles using anti-JUNV GP1 antiserum and anti-LCMV GP2 monoclonal antibody. Significantly less Arm-F260L protein was incorporated into 
virions, while showing equivalent or slightly increased levels in the corresponding cell lysates. Expression of the Arm-F260L GP also inhibited production of retroviral 
particles, as revealed by the anti-MLV CA antibody.
results in a protein that is more efficient at directing entry into 
cells, despite its adverse effects on incorporation into retroviral 
particles.
Differences in tropism o f clade B and Old World pseudotyped 
vectors
We next expanded our studies to examine the ability of the 
vectors to transduce a variety of different cell types. To monitor 
for any cell-specific effects on titer that were directed against 
retroviral components, such as host restriction factors that 
recognize the retroviral core (reviewed in Nisole et al., 2005), 
control vectors were included that were pseudotyped with the 
vesicular stomatitis virus glycoprotein (VSV-G). We found that 
the titers obtained varied with both the nature of the GP and the 
cell type examined (Table 1). However, similar to our findings 
with 293A cells, in several cell types that were permissive for 
entry directed by all the GPs, we observed lower titers for the 
JUNV and MACV GP pseudotyped vectors than the Old World 
pseudotypes (HeLa, NIH3T3, mES, IEC-6 and CEF cells).
We noted that human T and B lymphocytes (CEM, Jurkat, 
Nalm-6 and Raji cells) were completely resistant to LASV and
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Table 1
Titers a of pseudo typed vectors on various cell lines
Glycoprotein Human Simian Rodent Avian
HeLa K562 CEM Jurkat Nabil 6 Raji Vero NIH3T3 mES CHOK1 IEC-6 CEF
VSV-G 8.0 x 104 2.5 x 104 8.5 x 105 6.5 X 105 2.0 x 105 2.4 x 104 4.7 x 105 4.8 x 104 2.2 x 105 2.4 x 105 2.1 x 105 3.9 x 105
Old World
LASV 2.2 x 105 1.9 x 105 0 0 0 0 7.3 x 103 4.1 x 104 1.4 x 105 3.0 x 104 1.1 x 105 7.4 x 103
LCMV-Arm53b 2.8 x 105 6.3 x 103 0 0 0 0 1.4 x 103 4.4 x 104 4.7 x 104 6.1 x 103 1.1 x 104 4.5 x 103
LCMV-Arm53b(F260L) 2.0 x 105 4.4 x 103 0 0 0 0 2.2 x 103 5.6 x 104 5.7 x 104 8.3 x 103 1.8 x 103 8.0 x 103
New World clade B
JUNV 8.0 x 103 1.3 x 104 1.8 x 104 3.2 x 103 1.4 x 102 0 2.1 x 103 4.3 x 103 5.9 x 103 1.2 x 103 4.0 x 103 9.8 x 102
MACV 3.0 x 104 1.3 x 103 3.1 x 104 2.2 x 103 2.5 x 103 2.7 x 102 8.7 x 103 1.6 x 102 2.2 x 102 2.1 x 102 1.6 x 102 8.2 x 102
a Titers of pseudotyped retroviral vectors were measured by FACS analysis of transduced cells, 48 hrs post-transduction, and are shown as number of GFP-positive 
cells per ml of unconcentrated vector supernatant. Values shown are averages of 2-8 independent experiments.
LCM V vectors, while supporting reasonable titers for the JUNV 
and MACV vectors. It has previously been reported that both 
human and mouse lymphocytes are resistant to infection by 
LCMV (Borrow and Oldstone, 1992; Imperiali et al., 2005), 
probably because of incorrect glycosylation of a-DG in these 
cells (Imperiali et al., 2005). The mouse T lymphocyte cell line 
TIB-27 was also found to be resistant to transduction by LCMV 
GP pseudotyped vectors (data not shown). Orir data both 
confirm and extend these findings by demonstrating that this 
restriction can be conferred solely by the GP.
Lack of transduction of lymphocytes by Old World vectors 
occurs despite the presence of dystroglycan
A possible explanation for the lack of titer of the Old 
World vectors on human lymphocytes is that the cells do not 
express sufficient quantities of the presumed Old World 
receptor, a-DG. We addressed this possibility by performing 
Western blot analysis to examine the levels of dystroglycan 
on cells that were both permissive and non-permissive for 
transduction. However, analysis of the levels of a-DG proved 
technically difficult and we were unable to find an antibody 
that specifically and unequivocally detected the a-DG subunit 
on the complete panel of cell lines we looked at, despite 
using three different antibodies, IIH6, V1A4-1 and 1B7 (data 
not shown). To examine the levels of dystroglycan, we 
therefore resorted to using an anti-|’>-DG antibody, 43DAG/ 
8D5, raised against the extreme C-terminus of the human DG 
sequence. a-DG and |’>-DG are cleaved from the same 
precursor protein and remain associated by non-covalent 
interactions (Ibraghimov-Beskrovnaya et al., 1992). For 
several of the cell lines tested, we observed 3 bands at 
about 43, 37 and 25 kDa (Fig. 4). A similar pattern has also 
been observed in several carcinoma cell lines (Losasso et al., 
2000; Muschler et al., 2002), where the lower molecular 
weight bands are thought to arise by proteolytic processing of 
|3-DG (Losasso et al., 2000; Yamada et al., 2001). Using this 
antibody, we observed that all of the cell lines tested 
expressed |’>-DG and that there was no correlation between 
the ability of the arenavirus pseudotypes to enter cells and the 
overall levels of |’>-DG expression. A similar conclusion was 
reached in a recent study (Imperiali et al., 2005).
Despite the fact that we detected |’>-DG in human lymphoid 
cell lines, we noted that the lymphocytes had lower levels than 
the other human cell types (HeLa, 293A), suggesting the 
possibility that the levels of DG could be suboptimal for 
function as an arenavirus receptor in these cell types. 
Accordingly, we transduced CEM cells with a retroviral vector, 
pBabeDG, which contained the DG cDNA cloned into vector 
pBabeNeo (Morgenstern and Land, 1990). Following confir­
mation that this treatment increased the levels of DG in both 
CEM and control 293A cells (Fig. 5), we challenged the CEM- 
pBabeDG population with LASV and LCMV-Arm53b pseudo­
typed vectors. However, we still observed no transduction (data 
not shown).
We also examined whether CEM cells secreted an inhibitor 
of cell entry, such as soluble a-DG that could bind to the GP and 
interfere with subsequent cell binding and entry. However, 
incubation of 293A cells with supernatant from CEM cells had 
no effect on the titer of LASV or Arm53b pseudotyped vectors 
(data not shown).
Finally, we examined whether lymphocytes could be 
refractory to entry by Old World GP due to the presence of an 
inhibitory factor. We generated heterokaryons between non-
Fig. 4. [B-DG expression in various cell types. Twenty micrograms of cell lysates was loaded in each lane, and the Western probed with anti-|3-DG antibody. mES are 
murine ES cells, either knockout for DG expression (—/—) or the parental +/— cell line.
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Fig. 5. Over-expression of DG. 293A or CEM cells were transduced with 
retroviral vector pBabeDG, and the levels of DG examined 48 h later using 
Western blotting and an anti-|3-DG antibody. A significant increase in 
expression was observed in both cell types.
permissive CEM and permissive 293A cells by labeling each 
cell type, fusing the cells with PEG and FACS-sorting for the 
doubly labeled heterokaryons, as described (Abada et al., 2005). 
Subsequent challenge with LASV and Arm53b GP pseudotyped 
vectors demonstrated that the heterokaryons could be readily 
transduced by both vector types (Fig. 6). This finding rules out 
the presence of a dominant negative factor in the CEM cells that 
could act to inhibit the entry of the Old World viruses and 
instead suggests that these cells are simply lacking expression of 
a functional from of a necessary receptor or co-receptor 
molecule. The recent suggestion that the correct glycosylation 
of a-DG, and specifically O-mannosylation, is essential for its 
activity as a receptor for LCMV (Imperiali et al., 2005; Kunz et 
al., 2005) is in good agreement with our findings.
Requirement for a-DG in mouse ES cells
Our data so far strongly suggest that the New World clade B 
viruses use a different receptor(s) than the Old World viruses. In 
order to examine the requirements for a-DG in more detail, we 
compared the titers ofpseudotyped retroviral vectors on both DG 
knockout (-/-) and control heterozygous (+/-) murine ES cells 
(Williamson et al., 1997). Standard retroviral vectors are very 
inefficient at transducing murine ES cells, so it was necessary to 
perform these experiments using MND-based retroviral vectors. 
These vectors contain alterations in the long terminal repeat and 
5' untranslated regions of the MLV genome that combine to 
increase transduction of murine ES cells (Challita et al., 1995).
We determined the titer of a panel of pseudotyped MND 
vectors on the DG +/- and murine ES cells. Since retroviral 
vectors frequently give different titers when used to transduce 
individual clones derived from the same population, presum­
ably due to a number of factors that can affect the efficiency of 
transduction, we included VSV-G pseudotyped vectors as a 
positive control. Although the cell surface receptor for VSV-G 
is not clearly defined, VSV-G is not expected to be affected by 
the presence or absence of a-DG. Using this control, we 
observed consistent differences in titer for the VSV-G 
pseudotyped vectors on the two cell lines, with the titers on
Fig. 6. Heterokaryons formed between CEM and 293A cells are transduced by LASV GP pseudotyped vectors. (A) CEM and 293A cells were stained with CellTracker 
orange and green, respectively, fused with PEG, and the doubly staining heterokaryons isolated by FACS (arrowed population). (B) A typical transduced cell from the 
heterokaryon population following X-gal staining. Several dark blue staining nuclei are present in each cell, resulting from the expression of nuclear localized [3- 
galactosidase carried by the LASV GP vectors.
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Fig. 7. Effect of DG expression in murine ES cells on GP-directed titer. Titers of 
GP pseudo typed vectors were measured on DG —/— and +/— murine ES cells and 
the ratios determined. To correct for the different susceptibility of the two cell 
lines to transduction by retroviral vectors, all ratios were made relative to the 
VSV-G control in each experiment. Data shown are the mean ± SD for >5 
independent experiments.
the -/- cells being on average 55% of the level obtained on the 
+/- cells. To compensate for this and to allow direct comparison 
of the effect of the GP on titer between the -/- and +/- cells, we 
made all titers relative to the VSV-G control on the same cell 
line (Fig. 7).
These analyses revealed several interesting findings. First, 
we observed striking differences among the Old World viruses 
in their requirements for a-DG. While LASV GP had an 
absolute requirement for DG in murine ES cells, the two LCMV 
GPs were only somewhat affected, suggesting that LCMV can 
efficiently use an alternate receptor(s) to gain entry into murine 
ES cells. Previously, it has been reported that the clone 13 strain 
of LCMV has a significantly greater requirement for a-DG than 
the parental Arm53b strain, and our data agree with these 
findings since the F260L mutant was more sensitive to the loss of 
DG than Arm53b (P = 0.027). However, the fact that we still 
observed entry for vectors pseudotyped with the F260L mutant 
GP suggests that there may be differences between the GP 
pseudotyped vector system and the native virus that we are not 
aware of or could simply reflect a difference in sensitivity in the 
two systems.
This analysis also revealed that the clade B JUNV and 
MACV GPs do not require a-DG for entry since the ratio of 
titers on the two cell types was similar to the VSV-G control. 
These data agree with our findings of broad tropism for the 
clade B GP vectors on the panel of cell lines tested, including 
their ability to infect lymphocytes. Together, they demonstrate 
that the clade B viruses use receptor(s) other than a-DG.
Discussion
The identification of the cell surface receptor used by an 
enveloped virus can help to explain its tropism and increase our 
understanding of its pathogenicity and disease characteristics. 
In the arenaviruses, a-DG was previously identified as a 
receptor used by LASV, certain strains of LCMV and the New 
World clade C viruses (Cao et al., 1998; Spiropoulou et al., 
2002). Although it is likely that LCMV can use other receptor 
molecules and that the clade A and B New World viruses do not 
use a-DG (Spiropoulou et al., 2002), no other molecules have 
been proposed as receptors for this family.
Previous studies of arenavirus receptors have been per­
formed using a variety of in vitro assays, including binding 
assays and VOPBAs, together with virus infections using a-DG 
knockout murine ES cells (Borrow and Oldstone, 1992; Cao et 
al., 1998; Kunz et al., 2004; Smelt et al., 2001; Spiropoulou et 
al., 2002). The pseudotyped vector system that we have used in 
this work has distinct advantages for analyzing virus entry and 
receptor usage, including the ability to analyze the role of GP in 
the absence of other viral proteins. Importantly, these analyses 
can be performed under BSL-2 conditions, and similar systems 
have been widely used for other pathogenic enveloped viruses 
(Bartosch et al., 2003; Lin and Cannon, 2002; Wool-Lewis and 
Bates, 1998). Since the read-out in this system is an entry event 
(transduction), it is also likely to be a more accurate measure of 
functional GP-receptor interactions than can be obtained using 
in vitro assays since these are not always predictive of entry into 
cell lines. For example, the LCMV isolate PBL364 shows high 
affinity binding to a-DG in vitro yet has almost wild-type 
kinetics of infection on a-DG -/- murine ES cells (Kunz et al., 
2004), and VOPBA assays performed on rat intestinal epithelial 
cells were negative for Arm53b binding (Borrow and Oldstone, 
1992 ), despite our finding that Arm53b GP pseudotyped vectors 
can readily transduce these cells.
The pseudotyped retroviral vector system also has advan­
tages when compared to studies of entry made using infectious 
virus. Apart from the biosafety issues involved, viral infections 
are a complex system, where variations in tropism can be 
caused by proteins other than the GP. In addition, the 
arenaviruses have a short replication cycle coupled to a high 
mutation frequency of approximately 10 3 to 10 5 misincor­
porations per nucleotide site and round of copying (Domingo 
and Holland, 1997), leading to the generation of a large 
population of variants (Ruiz-Jarabo et al., 2003). Consequently, 
the biological properties of the variants may be very different 
from the original isolate used to initiate a culture or inoculate a 
host. Finally, such studies do not rule out the possibility that the 
lack of replication in certain cell lines is due to other, post-entry 
blocks to the arenavirus life-cycle.
Our study confirms and extends previous findings reported 
for arenavirus receptor usage by the Old World viruses. In 
agreement with Kunz et al. (2005), we found that LASV has an 
absolute requirement for a-DG in murine ES cells. However, in 
the context of pseudotyped retroviral vectors, we observed that 
the GP from the prototypic Arm53b isolate of LCMV was still 
able to transduce a-DG -/- murine ES cells at approximately 
30% the level of cells expressing a-DG. Previous studies have 
also reported lower levels of infection for LCMV isolates in the 
absence of a-DG (Kunz et al., 2003; Smelt et al., 2001). 
However, introducing the mutation F260L into the Arm53b GP, 
which mimics the change present in the clone 13 virus isolate, 
did not completely abolish transduction of -/- cells, although 
the ratio of transduction on the -/- to +/- cells was significantly 
lower than observed for the Arm53b isolate, indicating a greater 
dependence on a-DG for efficient entry.
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Overall, our data provide strong evidence for the existence of 
an alternate receptor on murine ES cells that can be used by 
LCMV but not by LASV. It is not clear at present whether this 
molecule represents a distinct receptor molecule in its own right 
or whether it normally functions as a co-receptor to a-DG that 
can be used, albeit less efficiently, in the absence of a-DG. Such 
a situation is known to exist in the primate immunodeficiency 
viruses, where the viral Env binds sequentially to both a primary 
receptor, CD4, and a co-receptor molecule such as CCR5, but 
where CD4-independent entry is observed for certain isolates of 
both SIV and HIV-1 (Dumonceaux et al., 1998, Edinger et al., 
1997). Clone 13 is reported to display both higher affinity for a- 
DG and a greater dependence on a-DG for entry than the 
Arm53b isolate (Kunz et al., 2004; Smelt et al., 2001). These 
two attributes are consistent with a model whereby the F26oL 
substitution could make the GP more dependent on a-DG 
binding to allow subsequent co-receptor binding, and thereby 
making a-DG-independent entry more difficult for this strain.
The marked discrepancy in the behavior of the LASV and 
LCMV pseudotyped vectors on a-DG -/- murine ES cells was 
not observed on any other cell type we examined, including 
other rodent cell lines (NIH3T3, IEC-6, CHO-K1). Instead, 
these Old World pseudotypes generally behaved in the same 
way, with titers falling in the same order of magnitude. Probably 
this reflects the dominance of a-DG as a receptor for these 
viruses.
For the Old World virus pseudotypes, we also consistently 
observed that T and B lymphocytes were non-permissive for 
entry. Recent work has demonstrated the importance of correct 
O-mannosylation of a-DG in order for it to serve as an 
arenavirus receptor (Imperiali et al., 2005; Kunz et al., 2005), 
and it is probable that the glycosylation state of DG in these 
cells underlies the block to arenavirus entry. Furthermore, 
binding studies that we have performed using a LASV GP1 
immunoadhesin and the T lymphocyte cell line CEM revealed 
that GP1 does not bind to these cells (Reignier et al., 
unpublished observations), which is consistent with this 
hypothesis. Interestingly, the lack of transduction of lympho­
cytes by the Old World vectors suggests that the alternate 
receptor present on murine ES cells that LCMV GP can use is 
not available on either human or murine lymphocytes.
For the New World clade B viruses that we studied, entry 
into murine ES cells directed by the JUNV and MACV GPs was 
unaffected by the loss of a-DG. These two GPs displayed a very 
broad tropism, transducing human, simian, rodent and avian cell 
lines and were able to enter human lymphocytes. Together, 
these data suggest that the receptor(s) that they use are likely to 
be distinct from any alternate receptors that could be utilized by 
LCMV in the absence of a-DG. The ability of the JUNV and 
MACV pseudotypes to transduce human lymphocytes is at odds 
with their in vivo tropism, where cells of the monocyte/ 
macrophage lineage are infected but not lymphocytes (Geisbert 
and Jährling, 2004). However, since viral tropism results from a 
complex set of interactions between a virus and a host cell, the 
ability of the JUNV and MACV GPs to direct entry into a cell 
does not necessarily predict a productive infection in that 
particular tissue in a patient.
Overall, our study reveals that receptor usage by the 
arenaviruses may be more complex than was previously 
appreciated. The search for the clade B receptor(s) and the 
alternate or co-receptors used by LCMV is an important goal for 
understanding more about the pathogenicity of these viruses.
Materials and methods
Cell lines
293A, 293T, Vero, HeLa, Cos-7, NIH 3T3, CHOK1, TIB- 
27 and IEC-6 cells were maintained in Dulbecco’s modified 
Eagle’s medium (DMEM) (Mediatech, Herndon, VA), with 
10% fetal bovine serum (FBS) (Hyclone, Logan, UT) and 
2 mM glutamine (Gibco BRL, Grand Island, NY). Raji, 
Jurkat, CEM and Nalm-6 cells were maintained in RPMI 
(Irvine Scientific, Santa Ana, CA) supplemented with 10% 
FBS and 2 mM glutamine. Dystroglycan-null knockout (-/-) 
and heterozygous control (+/-) R1 murine embryonic stem 
(ES) cells (Williamson et al., 1997) were generously 
provided by Dr. Kevin Campbell, University of Iowa. 
These cells were grown in DMEM supplemented with 20% 
FBS, 2 mM glutamine, 1 mM non-essential amino acids, 
0.001% p>-mercaptoethanol and 103 units/ml of LIF 
(ESGRO, Chemicon, Temecula, CA). All cells were main­
tained in 5% CO2 except the TIB-27 cells which were 
maintained in 10% CO2.
Arenavirus glycoproteins
The GP from the Armstrong 53b (Arm53b) strain of LCMV 
(Southern et al., 1987) was kindly provided by Gabor Veres 
(Cell Genesys), expressed from the CMV immediate early 
promoter in vector pCI (Promega, Madison, WI). When 
compared to the original database sequences of Arm53b GP 
(accession number NP_6948514), two differences were found, 
R177A and A313E. These changes are also present in two other 
database sequences for LCMV GP (accession numbers 
AAX49341.1 and P09991) and were also observed in two 
independent isolates of Arm53b that we cloned from a virus 
stock kindly provided by Dr. M. Suresh (University of 
Wisconsin, Madison). The clone 13 variant of LCMV- 
Arm53b GP contains the substitution F26oL (Salvato et al., 
1988 ), and this mutation was introduced into the Arm53b GP to 
generate Arm53b-F26oL. The GP from LASV (Josiah strain, 
accession no. AY628203) was expressed in vector pCAGGS 
(Niwa et al., 1991). A sequence corresponding to the reported 
database sequence of JUNV GP (Parodi strain, accession no. 
U70799) was derived from genomic fragments of the JUNV S 
strand (Albarino et al., 1997) and cloned into the CMV 
immediate early promoter expression plasmid pSA90 (Soneoka 
et al., 1995). Tacaribe virus (TACV) GP was cloned by RT-PCR 
from total RNA isolated from infected Vero cells and cloned 
into the CMV immediate early promoter expression vector 
pCAGGS. It differs from the database sequence for strain TRVL 
11598 (accession number P31840) at two positions, R233H and 
E446R. The GP from MACV (Carvallo strain, accession no.
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AY129248) was synthesized as a codon optimized open-reading 
frame and cloned into the pCAGGS.
Retroviral vector production and titer determination
Retroviral vectors displaying arenavirus GPs were produced 
by transient transfection of plasmids pCgp (Han et al., 1998 ), 
pMND-eGFP (Zheng et al., 2004) or pCnBg (Han et al., 1998) 
and the appropriate GP expression plasmid into 293T cells, 
essentially as described (Christodoulopoulos and Cannon, 
2001; Han et al., 1998). The pCgp plasmid expresses murine 
leukemia virus (MLV) Gag-Pol, and plasmids pMND-eGFP and 
pCnBg are retroviral vector genomes expressing enhanced 
green fluorescence protein (eGFP) or nuclear-localized fJ- 
galactosidase, respectively, as reporter genes. Retroviral vector 
supernatants were harvested 48 h post-transfection filtered 
through a 0.45 mm filter (Millipore Corp., Bedford, MA), and 
aliquots were stored at -80 °C. Titers were determined by 
incubation of serially diluted vector stocks with target cells for 
48 h followed by calculation of percent positive cells, either by 
X-gal staining for |’>-galactosidasc expression (Christodoulo­
poulos and Cannon, 2001) or by FACS analysis for eGFP 
expression.
Western blot analysis
For detection of |’>-dysti'oglycan (|’>-DG), cells were lysed 
in lysis buffer (20 mM Tris-HCl [pH 7.5], 1% Triton X-100, 
0.05% sodium dodecyl sulfate [SDS] containing 5 mg/ml 
sodium deoxycholate, 150 mM NaCl and 1 mM phenyl­
methylsulfonyl fluoride [Sigma]) at 4 °C for 10 min, 
centrifuged in an Eppendorf micro luge at 16,000 x g for 
10 min and the cleared supernatants were diluted 1:1 in 2 x 
SDS gel loading buffer (Biorad, Hercules, CA) plus 5% 2- 
mercaptoethanol, boiled for 10 min and electrophoresed in 8- 
16% polyacrylamide gels (Biorad). The proteins were 
transferred to an Immobilon P polyvinylidene fluoride transfer 
membrane (Millipore Corp., Bedford, MA) and blocked 
overnight at 4 °C with blocking buffer (5% dried milk in 
PBST [PBS {pH 7.4}, 0.1% Tween 20]). £>-DG was detected 
using the 43DAG1/8D5 antibody (Novocastra Laboratories 
Ltd, Newcastle upon Tyne, UK) at a 1:50 dilution in blocking 
buffer followed by horseradish-peroxidase-conjugated goat 
anti-mouse IgG (1:10,000) (Pierce, Rockford, IL). Specific 
proteins were visualized using the enhanced chemilumines­
cence detection system (Amersham Biosciences Corp., Piscat­
away, NJ).
Viral GPs in either cell lysates or retroviral particles were 
detected by Western blot analysis of cell lysates or 
concentrated virus supernatants, essentially as described 
(Christodoulopoulos and Cannon, 2001). The antibodies 
used were the anti-LASV GP monoclonal antibody L52- 
161-6 (Ruo et al., 1991) at a 1:10,000 dilution, the anti-JUNV 
GP monoclonal antibody QD04 AF03 (Sanchez et al., 1989; 
York et al., 2005) at a 1:2000 dilution, the anti-LCMV GP2 
monoclonal antibodies WE-83.6 (Parekh and Buchmeier, 
1986) at 1:100 dilution and 2704 (Parekh et al., 1989) at a 
1:3000 dilution. Retroviral vector particles were detected 
using the goat anti-Rauscher MLV CA antiserum (Quality 
Biotech, Camden, NJ) at a 1:10,000 dilution. Where required, 
viral proteins were deglycosylated by incubation with peptide 
N-Glycosidase F (PNGase F; New England Biolabs, Ipswich, 
MA) for 90 min at 37 °C, using 750 units of enzyme for 
20 pg of total protein.
Heterokaryon analysis
CEM and 293A cells were stained by incubation for 45 min 
at 37 °C in growth media containing 1 mM CellTracker green 
(Molecular Probes, Eugene, OR) for CEM cells, or 10 mM 
CellTracker orange (Molecular Probes) for 293A cells, 
essentially as described (Abada et al., 2005). A mix ture of 
1 x 107 of each labeled cell type was fused by the addition of 
1 ml of 50% polyethylene glycol (PEG) with a molecular mass 
of 3000 Da (Sigma) in 2% glucose, as described (Abada et al., 
2005). Following overnight incubation, the doubly labeled 
population was sorted using a FACS DIVA (Becton Dickinson, 
San Jose, CA) with an excitation laser frequency of 488 nm and 
emission detected at 525 nm. The sorted cells were plated in 6- 
well plates, and 48 h later, the heterokaryons were challenged 
with LASV or LCMV-Arm53b pseudotyped retroviral vectors 
expressing nuclear localized |’>-galactosidasc (vector pCnBg). 
Staining with X-gal (Han et al., 1998) and microscopic 
examination were used to determine whether the heterokaryons 
had been transduced.
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